

# Effect of RYGB on the absorption of metoprolol controlled release.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Pending
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON21648

### Source

Nationaal Trial Register

### Health condition

Roux- en Y gastric bypass  
metoprolol  
controlled release tablet  
absorption

gastric bypass  
metoprol  
tablet met gereguleerde afgifte  
absorptie

## Sponsors and support

**Primary sponsor:** Medisch Centrum Leeuwarden  
Leeuwarden

**Source(s) of monetary or material Support:** Wetenschapsfonds MCL

## Intervention

## Outcome measures

### Primary outcome

1 - Effect of RYGB on the absorption of metoprolol controlled release. 17-05-2025

Parameters that will be determined before and after surgery are C<sub>max</sub>, T<sub>max</sub> and AUC<sub>0-24</sub> of metoprolol and its main active metabolite  $\alpha$ -OH metoprolol.

The main endpoint is the ratio of AUC<sub>after</sub>/AUC<sub>before</sub> of metoprolol and  $\alpha$ -OH metoprolol.

### **Secondary outcome**

Secondary endpoint is the quotient of the ratios of the AUC of metoprolol and its metabolite after and before.

Other study parameters

Blood pressure and heart rate measured at t = 0, 2, 4, 8 and 10 hours after intake of metoprolol.

Further analysis

After completion of the other pharmacokinetic study with metoprolol immediate release tablet relevant parameters may be compared for further analysis.

## **Study description**

### **Background summary**

Rationale: Bariatric surgery induces changes in the gastrointestinal tract that might alter the pharmacokinetics of drugs, especially for oral medication with a coating or with a controlled release profile.

Hypothesis: Bariatric surgery influences the rate and extent of absorption of a lipophilic drug like metoprolol from a tablet with a controlled release (CR) profile.

Objective: To investigate the effect of Roux-en-Y gastric bypass on the rate and extent of absorption of metoprolol and its main active metabolite  $\alpha$ -OH metoprolol, after a single oral dose of 95 mg metoprolol CR tablet in 10 female bariatric surgery patient volunteers, before and after surgery.

Study design: A single dose, fasting, explorative pharmacokinetic study before and after surgery, with the patient as his own control.

Study population: 10 female bariatric surgery patient volunteers between 18 and 50 years

old.

Intervention: One month before and six months after Roux-en-Y gastric bypass the patient takes a single oral dose of 95 mg of metoprolol CR tablet.

Main study parameters/endpoints: Parameters that will be determined before and after surgery are C<sub>max</sub>, T<sub>max</sub> and AUC<sub>0-24</sub> of metoprolol and its main active metabolite  $\alpha$ -OH metoprolol. The main endpoint is the ratio of AUC<sub>after</sub>/AUC<sub>before</sub> of metoprolol and  $\alpha$ -OH metoprolol.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There will be no direct benefit for included patients. After having given written informed consent to participate in the study, the patient is required to undergo a medical examination. The patient has to visit the MCL for two days. The first visit is scheduled one month before the surgery and the second visit six months after surgery. The procedure of both visits is the same. A single dose of 95 mg of metoprolol may cause side effects like hypotension, headache and dizziness, but these side effects are moderate. Blood pressure and heart rate will be monitored regularly. The patient is not allowed to lie down during the first six hours of the study. During each visit, 11 blood samples of each 5 ml will be collected according to a time schedule by a venous cannula. An intensivist is available for questions and safety of the patient. The patient has to stay at the clinical research unit, but is not confined to bed.

## **Study objective**

Obesity is a growing world wide problem. In The Netherlands, about 10% of all men and women have a BMI of 30 kg/m<sup>2</sup> or more. Obesity is a chronic, incurable metabolic disorder, which is characterised by excessive fatstorage at unfavorable places. Obese people have a higher risk to develop comorbidities like diabetes mellitus II, cardio vascular diseases and osteoarthritis. Morbid obesity, a BMI  $\geq$  40 kg/m<sup>2</sup>, is also associated with reduced life expectancy.

Bariatric surgery is an operation for obese people with a BMI  $\geq$  40 kg/m<sup>2</sup> or  $>35$  kg/m<sup>2</sup> with a comorbidity, who are not able to lose weight by themselves. The number of patients undergoing bariatric surgery is rapidly increasing. Several metabolic operations can be divided into a restrictive (gastric band, sleeve gastrectomy), a malabsorptive (biliopancreatic deviation) and a combined restrictive/malabsorptive (gastric bypass) procedure. In The Netherlands the Roux-en-Y gastric bypass is the most frequently performed operation, with the best long term results. Bariatric surgery has been shown to lead to sustained weight loss, resolution of comorbidities and improved life expectancy.

Theoretically, bariatric surgery may alter the pharmacokinetics of orally taken drugs. Depending on the type of operation, different factors might influence drug absorption. A gastric restriction has influence at gastric mixing, gastric pH and gastric emptying. These changes may influence drug absorption by an altered drug disintegration and dissolution. Secondly, because of the reduced functional gastrointestinal length after a bypass procedure the absorption of drugs across the duodenum and jejunum might be reduced. This might be counterbalanced by "intestinal adaptation", whereby mucosal hypertrophy within the remaining intestine results in an increased absorptive capacity.

Altered drug absorption will be a problem especially for oral formulations with a coating or with a modified release profile. These technological formulations are developed to disintegrate at a higher pH, or to dissolve slowly. In the USA investigators advocate that formulations with controlled release should not be used after bariatric surgery. However this is based on theoretical aspects and not on clinical studies.

The absorption of lipophilic drugs might be decreased because bile salts may emulsify the lipophilic drugs for absorption much later. Results showed that after a partial gastric resection the absorption of the lipophilic  $\beta$ -blocker propranolol is significantly decreased compared to the hydrophilic  $\beta$ -blocker atenolol. Although bariatric surgery may theoretically have effect on the pharmacokinetics of drugs, there is little known about the pharmacokinetics of drugs after bariatric surgery. In this study we want to investigate the pharmacokinetic profile of a controlled release lipophilic drug before and after a Roux-en-Y gastric bypass.

Preliminary results of a retrospective study show that metoprolol belongs to the top 15 of most used drugs by bariatric surgery patients. The majority of these patients use metoprolol as a controlled release formulation. For these reasons metoprolol CR will be used in this study. However another pharmacokinetic study with metoprolol immediate release will also be performed. To determine the effect of the Roux-en-Y gastric bypass, the rate and extent of absorption of metoprolol CR before and after this surgery will be compared. In this study, the patient is his own control.

## **Study design**

A single oral dose of 95 mg metoprolol CR tablet will be administered in 10 female bariatric surgery patient volunteers, one month before and six month after surgery. After intake a serum concentration time curve will be determined for metoprolol and its active metabolite by collecting and analysing blood samples.

## **Intervention**

A single dose, fasting, explorative pharmacokinetic study before and after surgery, with the patient as his own control.

This study concerns an explorative two-phase single oral dose pharmacokinetic study of metoprolol under fasting conditions in patients undergoing bariatric surgery. The single dose will be administered twice in each patient, once before and once after bariatric surgery.

The study will be performed in 2013-2014.

The study takes place at the clinical research unit of the MCL. Analysis of the samples will

take place in the Laboratory for Drug Analysis and Clinical Toxicology of the Department of Clinical Pharmacy and Clinical Pharmacology MCL.

#### Details

- A total of 10 female bariatric surgery patient volunteers will participate in this study.
- The study is divided into two periods. One period before scheduled surgery and one after surgery.
- Metoprolol succinate 95 mg controlled release tablet will be used.
- The patient will stay at the MCL for 10 hours.
- Each visit, a total of 10 blood samples of 5 ml will be collected
- 24 hours after the intake of the tablet a blood sample of 5 ml will be collected at the patient's home
- Blood pressure and heart rate will be monitored.
- Four months after surgery before the start of the second phase of the study the patient will be asked about dumping syndrome symptoms by means of a questionnaire. Dumping syndrome is characterized by symptoms of nausea, shaking, sweating, diarrhea, light-headedness, flushing, tachycardia (fast heart rate) and possibly fainting shortly after eating foods containing high amounts of refined sugars and when eating too fast. Side effects of metoprolol might resemble these symptoms. If the patient is suffering from the dumping syndrome, the patient will be withdrawn from the study.

## Contacts

#### **Public**

Medisch Centrum Leeuwarden<br>  
Henri Dunantweg 2  
J.P. Yska  
Leeuwarden 8934 AD  
The Netherlands  
+31 (0)58 2866604

#### **Scientific**

Medisch Centrum Leeuwarden<br>  
Henri Dunantweg 2  
J.P. Yska  
Leeuwarden 8934 AD

## Eligibility criteria

### Inclusion criteria

- Female gender;
- Age 18-50 years;
- Scheduled for Roux-en-Y gastric bypass surgery;
- Good liver and kidney function;
- Normal ECG;
- Intermediate or extensive CYP 2D6 metabolizer, evidenced by genotyping.

### Exclusion criteria

- Pregnancy;
- Smoking;
- Alcohol: more than 7 drinks a week or 4 or more drinks during a single occasion (12);
- Use of alcohol during the period 24 hours before until 48 hours after the start of each phase of the study;
- Use of metoprolol;
- The use of CYP 2D6 inhibiting, inducing or metabolising drugs;
- The use of drugs that may interact with metoprolol;
  - o Calcium antagonist;
  - o Lidocaine;
  - o Digoxin;

- An existing contraindication for the use of metoprolol (8);
  - o Sick-sinus syndrome;
  - o Second and third degree heart block;
  - o Systolic blood pressure less than 100 mmHg;
  - o Cardiogenic shock;
  - o Sinus bradycardia;
  - o Cardiac failure, overt;
  - o Cardiac failure, moderate to severe;
  - o Untreated pheochromocytoma;
  - o Heart rate less than 45 beats/minute;
  - o First degree heart block (P-R interval 0.24 sec or greater);
  - o Severe bronchial asthma or a history of severe bronchospasm;
  - o Hypersensitivity to metoprolol, related derivatives, other beta-blockers, or any component of the product;
  - o Severe peripheral arterial circulatory disorders;
- Previous surgery of the upper gastrointestinal tract;
- Disease or any other condition that may interfere with gastrointestinal absorption;
- Suffering from dumping syndrome after RYGB surgery;

## Study design

### Design

Study type:	Interventional
Intervention model:	Crossover
Allocation:	Non controlled trial

Masking:	Open (masking not used)
Control:	N/A , unknown

## Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-09-2013
Enrollment:	10
Type:	Anticipated

## Ethics review

Positive opinion	
Date:	20-05-2013
Application type:	First submission

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
NTR-new	NL3833
NTR-old	NTR4001
Other	MCL-metoprolol-CR : RTP0 897
ISRCTN	ISRCTN wordt niet meer aangevraagd.



## Study results